US Stock MarketDetailed Quotes
GRI GRI Bio
- 0.990
- -0.050-4.81%
Close Nov 5 16:00 ET
2.90MMarket Cap-95P/E (TTM)
1.030High0.910Low1.26MVolume1.030Open1.040Pre Close1.20MTurnover47.54%Turnover RatioLossP/E (Static)2.93MShares115.57052wk High0.61P/B2.63MFloat Cap0.30252wk Low--Dividend TTM2.65MShs Float28282.800Historical High--Div YieldTTM11.50%Amplitude0.301Historical Low0.954Avg Price1Lot Size
About GRI Bio Company
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.
Company Profile
SymbolGRI
Company NameGRI Bio
Listing DateFeb 10, 2021
Founded2009
CEODr. W. Marc Hertz, PhD
MarketNASDAQ
Employees4
Fiscal Year Ends12-31
Address2223 Avenida De La Playa,Suite 208
CityLa Jolla
ProvinceCalifornia
CountryUnited States of America
Zip Code92037
Phone1-619-400-1170
Websitehttp://www.gribio.com
Company Executives
- Name
- Position
- Salary
- Dr. W. Marc Hertz, PhD
- President, Chief Executive Officer, and Director
- 842.01K
- Dr. Albert Agro, PhD
- Chief Medical Officer
- 406.99K
- Leanne M. Kelly
- Chief Financial Officer and Principal Accounting Officer
- 665.28K
- Dr. Vipin Kumar Chaturvedi, PhD
- Chief Scientific Officer
- --
- David Szekeres
- Chairman of the Board
- 152.84K
- David Baker
- Director
- 117.21K
- Roelof Rongen
- Independent Director
- 129.44K
- Camilla V. Simpson, M.Sc.
- Independent Director
- 134.33K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data